Insider Transactions in Q4 2025 at Avalo Therapeutics, Inc. (AVTX)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2025
|
Christopher Ryan Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
155
-0.89%
|
$620
$4.1 P/Share
|
|
Dec 10
2025
|
Paul Varki Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,016
-21.85%
|
$4,064
$4.1 P/Share
|
|
Dec 10
2025
|
Jennifer Riley Chief Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
637
-19.35%
|
$2,548
$4.1 P/Share
|
|
Dec 10
2025
|
Mittie Doyle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,013
-21.86%
|
$4,052
$4.1 P/Share
|
|
Nov 14
2025
|
Jonathan Goldman Director |
SELL
Open market or private sale
|
Direct |
11,367
-100.0%
|
$159,138
$14.33 P/Share
|
|
Nov 14
2025
|
Jonathan Goldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,200
+50.0%
|
$73,800
$9.88 P/Share
|